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The

port-wine stains through greater vessel heating
and deeper vascular injury.2 The improved technology targets the heterogeneity in blood-vessel
sizes that is characteristic of port-wine stains.3
Any study evaluating the response of port-wine
stains to treatment should include an analysis
based on the location of the anatomical malformation and the patient’s age. As compared with
other areas of the face and neck, port-wine stains
on the center of the face have been shown to respond less effectively to treatment and are more
likely to recur.4 An aggressive approach to treating infants and young children can also allow for
more rapid and complete clearing.5
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The Authors Reply: With ongoing research in
medicine, investigating the 10-year follow-up results of any medical treatment inevitably leads to
somewhat outdated results at the time of presentation. This is especially the case in a field that is
subject to continuous development, such as pulseddye–laser treatment of port-wine stains. As Nelson
and Geronemus point out, the results with newer
pulsed-dye lasers have been reported to be promising and superior to the results with the laser
used in our study. However, to date no controlled
comparative studies have shown improved clinical
efficacy. Whether the new lasers have improved
long-term efficacy remains to be reported; in
light of our observation of the recurrence of portwine stains, we certainly hope they do.
No differences or trends in responses to treatment related to the anatomical locations of the
port-wine stains were observed in either the origi
nal study1,2 or the current follow-up study, possi
bly because of the relatively small number of patients. Furthermore, in the original study, age was
shown to have no influence on the response to
treatment. Therefore, we refrained from performing age-dependent analyses in the current longterm follow-up assessment.
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Chantal M.A.M. van der Horst, M.D., Ph.D.
Academic Medical Center
1100 DE Amsterdam, the Netherlands
m.huikeshoven@amc.uva.nl
1. van der Horst CMAM, Koster PHL, de Borgie CAJM, Bossuyt

PMM, van Gemert MJC. Effect of the timing of treatment of portwine stains with the flash-lamp–pumped pulsed-dye laser.
N Engl J Med 1998;338:1028-33.
2. Kauvar AN, Geronemus RG. Treatment of port-wine stains.
N Engl J Med 1998;339:635-6.

Treatment of Kawasaki Disease
To the Editor: In their trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease, Newburger et al. (Feb. 15 issue)1
report that, as compared with placebo, a single
pulsed dose of corticosteroid resulted in a shorter
initial period of hospitalization but that the total
numbers of days of fever and hospitalization, the
rates of retreatment, and the coronary-artery outcomes did not differ significantly between the two
groups. The use of a single-dose regimen without
tapering most likely contributed to their results.
A single application of a corticosteroid, even at a
high dose, may have a strong but only short-lived
2746
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effect, which could therefore be associated with
a secondary increase in inflammation.
On the basis of nearly 10 years of clinical
experience,2 we designed a regimen involving a
short intravenous course of prednisolone and
subsequent oral administration of prednisolone
followed by tapering.3 In a randomized trial performed to test the effectiveness of the regimen
as an adjunct to intravenous immune globulin,
the incidences of retreatment and coronary-artery
abnormalities within 1 month after the start of
treatment were less frequent in the corticosteroid
group than in the group receiving immune globu-

www.nejm.org

june 28, 2007

Downloaded from www.nejm.org at THOMAS JEFFERSON UNIVERSITY on October 1, 2007 .
Copyright © 2007 Massachusetts Medical Society. All rights reserved.

correspondence

lin alone. Our regimen therefore appears to be Andrea Taddio, M.D.
more efficacious than the control regimen. Never Institute of Child Health
Trieste, Italy
theless, the optimal corticosteroid regimen re- 34100
ataddio@yahoo.it
mains an issue in the primary therapy of KawaCarlos D. Rosé M.D.
saki disease.
Thomas Jefferson University
Yoshinari Inoue, M.D.
Wilmington, DE 19803
Tohru Kobayashi, M.D.
1. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatAkihiro Morikawa, M.D.
ment for immune globulin-resistant Kawasaki disease: a comGunma University Graduate School of Medicine
Gunma 371-8511, Japan
yinoue@showa.gunma-u.ac.jp
1. Newburger JW, Sleeper LA, McCrindle BW, et al. Random-

ized trial of pulsed corticosteroid therapy for primary treatment
of Kawasaki disease. N Engl J Med 2007;356:663-75.
2. Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease.
J Pediatr 1999;135:465-9.
3. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for
Kawasaki disease: clinical course and coronary artery outcome.
J Pediatr 2006;149:336-41.

To the Editor: Newburger et al. studied the effects of adding intravenous methylprednisolone to
conventional therapy for Kawasaki disease. The
authors found a significantly lower frequency of
coronary-artery abnormalities in the intravenousmethylprednisolone group than in the placebo
group within the subgroup of patients who required retreatment with intravenous immune
globulin.
The identification of predictors of coronary ab
normalities in Kawasaki disease is still problematic. Failure of initial treatment with intravenous
immune globulin remains the most consistent
risk factor for cardiac abnormalities.1 Administration of intravenous methylprednisolone after
the failure of initial treatment with intravenous
immune globulin does not seem to be effective in
reducing the risk of coronary damage,2 although
the current data suggest that this might not be the
case for patients who do not have a response to
intravenous immune globulin and who have previously received intravenous methylprednisolone.
Since intravenous methylprednisolone administered as a single dose appears to be safe,3 and
given our inability to identify a priori the patients
who will not have a response to intravenous immune globulin, it seems obvious that the concurrent use of a single dose of intravenous methylprednisolone and intravenous immune globulin
may be our best choice at the moment. It is unrealistic to expect that trials powered to show
the effectiveness of intravenous methylprednisolone could be accomplished anytime soon.

parative study of additional immune globulin and steroid pulse
therapy. Pediatr Int 2001;43:211-7.
2. Lang BA, Yeung RS, Oen KG, et al. Corticosteroid treatment
of refractory Kawasaki disease. J Rheumatol 2006;33:803-9.
3. Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a
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To the Editor: Although the study by Newburger
et al. involved assessment of coronary-artery outcomes with the use of transthoracic echocardiography, we were quite surprised by the inclusion
of an example of a coronary aneurysm seen on
multidetector computed tomography (CT) in the
accompanying Perspective article by Burns.1
We and others2,3 have shown the efficacy of
noninvasive magnetic resonance imaging (MRI)
of the heart for both the identification and characterization of coronary artery disease in patients
with Kawasaki disease (Fig. 1). Patients with
Kawasaki disease require frequent observation
over many decades. Given the relatively high doses
of ionizing radiation associated with multidetector
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Figure 1. Three-Dimensional Steady-State Free-Precession
MRI of the Whole Heart in an 8-Year-Old Boy with
Kawasaki Disease and Serial Aneurysms (A) in the
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CT4 and the heightened potential for radiationinduced fatal cancer in children,5 we believe that,
if transthoracic echocardiography is inadequate,
these younger patients are best served by the use
of coronary MRI.
Gerald F. Greil, M.D.
King’s College London
London SE1 9RT, United Kingdom
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The Authors Reply: Inoue and colleagues describe the results of their open trial using a prolonged course of corticosteroids, which we discuss
in our article. We found that clinically significant
coronary-artery abnormalities were infrequent in
patients in both of our study groups. For this
reason, although the optimal corticosteroid regimen may be unknown, we believe that corticosteroid regimens requiring a prolonged course of
treatment would be difficult to rationalize for the
primary treatment of all patients with Kawasaki
disease.
Taddio and Rosé highlight an important question arising from our analyses. Our study was de
signed to test the hypothesis that the addition of
intravenous methylprednisolone to conventional
primary treatment of Kawasaki disease would im
prove coronary-artery outcomes; the study groups
had similar overall coronary outcomes. A post hoc
subgroup analysis suggested that primary cortico
steroid therapy reduced the incidence of coronaryartery abnormalities in a high-risk subgroup of
patients in our study who required retreatment
with intravenous immune globulin because of
persistent or recrudescent fever. However, such
subgroup analyses must be interpreted with caution1; the literature is replete with subgroup
analyses suggesting differential responses to
2748
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therapy, findings that have been shown to be erroneous in subsequent prospective trials.2 Children with Kawasaki disease can be characterized
at the time of presentation with respect to their
risk of resistance to intravenous immune globulin.3 Until further studies are conducted in highrisk patients, we do not believe that corticosteroid
therapy should be used in the primary treatment
of Kawasaki disease.
Jane W. Newburger, M.D., M.P.H.
Children’s Hospital
Boston, MA 02115
jane.newburger@cardio.chboston.org
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Dr. Burns Replies: Imaging of the coronary arteries is important in the long-term management
of aneurysms in patients with Kawasaki disease.
Transthoracic echocardiography can be used only
to image the proximal arteries, is dependent on a
high level of technical skill, and cannot reliably
detect stenosis. Advantages of multidetector CT
are the assessment of calcification and soft plaque,
rapid collection of data, and straightforward interpretation of images. With proper gating to the
cardiac cycle and lowering of the heart rate with
beta-adrenergic blockade, exposures of approximately 0.67 mSv have been documented for coronary-artery studies of children involving multidetector CT (Larkin G, GE Healthcare: personal
communication) (for comparison, one chest radiograph results in exposure to 0.02 mSv). MRI is safe,
but many centers cannot image the coronary arteries with sufficient precision. All these approaches require general anesthesia for young
patients, and MRI requires a longer time to capture images than does multidetector CT and thus
increases the time under anesthesia and associated risks. Clearly, this is an area of medicine that
is in flux. We look forward to the time when safe,
noninvasive imaging methods are widely available at all centers for these children.
Jane C. Burns, M.D.
University of California, San Diego
La Jolla, CA 92093-0830
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